Biotech Movers: Luminex, Exelixis, AMAG Pharmaceuticals

Shares of Luminex (LMNX) rose 14.4% to $21.65 in premarket trading on Tuesday. The Austin, Texas-based firm after the market close on Monday reported first-quarter adjusted net income of $12.16 million, or $0.28 per share, compared with $12.18 million, or $0.29 per share in the year-ago period. Consolidated revenue was $77.8 million, up 23% year-over-year.

Luminex increased its 2017 annual revenue guidance range to between $300 million and $310 million, from between $295 million and $305 million. The company said it expects revenue for the second quarter to be
between $74 million and $76 million.

Shares of Exelixis (EXEL) were up 6.1% to $24.55 after the  South San Francisco, Calif.-based firm unveiled first-quarter results after the market close on Monday. Exelixis reported net income of $16.7 million, or $0.05 per diluted share, compared with a net loss of $59.2 million, or $0.26 per share, in the same period in 2016. Revenue was $80.9 million, versus $15.4 million in the year-ago period.

The company reaffirmed previous guidance that total costs and operating expenses for the full year will be between $290 million and $310 million.

Shares of AMAG Pharmaceuticals (AMAG) were down 5.9% to $23.20. The Waltham, Mass.-based firm on Tuesday reported a first-quarter operating loss of $40 million, compared to operating income of $7.4 million in the first quarter of 2016.

"The operating loss in the first quarter of 2017 was primarily due to a one-time payment of $60 million to Palatin Technologies, Inc. related to the bremelanotide licensing transaction," AMAG said.

The company reported non-GAAP adjusted Ebitda of $57.6 million, up about 21% year-over-year. Total GAAP revenue was $139.5 million, up about 28% compared to the year-ago period.

Also on Tuesday, the company announced positive data from a phase three study of Feraheme (ferumoxytol) compared to Injectafer (ferric carboxymaltose injection) in adults with iron deficiency anemia.

More from Health

Can Legal Cannabis Help Slow the Opioid Drug Epidemic in the U.S.?

Can Legal Cannabis Help Slow the Opioid Drug Epidemic in the U.S.?

How to Become a Physician Assistant: What to Know

How to Become a Physician Assistant: What to Know

What is THC? Experts Weigh in on the Compound's Benefits and Effects

What is THC? Experts Weigh in on the Compound's Benefits and Effects

How Much Does a Physician Assistant Make?

How Much Does a Physician Assistant Make?

Buy These 3 Risky Biotech Stocks

Buy These 3 Risky Biotech Stocks